Mr Gilbert Reveillon
Present in 146 countries, CCEs form an active network of over 4,000 members at the service of French companies around the world.
Selected for their competence and their international experience, the 'Conseillers du Commerce extérieur de la France' (CCE - French Foreign Trade Advisor) are appointed for three years through a prime ministerial decree, on the recommendations of the Minister for Foreign Trade. For more than 115 years, on a voluntary basis, they have been placing their experience at the service of France's economic presence around the world.
Mr Olivier RICHART
Ophthalmology
Orthopedics/Orthopedic Surgery
Your innovative solution
SoTube/SoSafe are two innovative medical packaging solutions, nested tubes based, for implants double-sterile barrier packaging. Compared to double-pouches/double-blisters, these double-tubes ensure nurses and surgeons easy handling of package and implant as well as a pioneer 100% No Touch approach right up to the point of surgery.
Their benefits over traditional packages: 10 times smaller and lighter than traditional packages, more eco-friendly, "NoTouch" approach capability reducing aseptic faults in the operating room, 5 years shelf life and sterility guaranteed, fast opening, secured manipulation, storage optimization, reduce operating time, easy to implement, economy & marketing edge, etc.
Orthopedic / Foot and hands / Spine /
1: Patented products and its no touch application / 2: CE marked and FDA approved / 3: storage optimization / 4: easier identification and manipulation
Selenium Medical
CEOFRANCK ROBERT
Obstetrics/Gynecology (Women's Health)
Oncology
Ophthalmology
Orthopedics/Orthopedic Surgery
Pediatrics/Neonatology
Pulmonary/Respiratory Diseases
Psychiatry/Psychology
Your innovative solution
Hospital Manager is a cloud-based and integrated Hospital Information System. Designed on a single patient-centered database and a multi-tenant architecture, our solution has been designed since its inception to facilitate the coordination of multidisciplinary care providers within the patient's health continuum. Hundreds of institutions have chosen our solution for the richness of its features and the power of its technologies.
Challenges facing the healthcare industry today are not only to improve patient care and safety but also to optimize healthcare costs. Many hospitals struggle with out-dated, silo-designed and not inter-connected systems. Care teams waste time hunting for missing information. More and more institutions are merging to increase their operational and financial efficiencies.
Market segment 1: Hospitals Market segment 2: Imaging centres
Advantage 1: our solution allows developing teamwork around the patient. Designed for a variety of users (physicians, pharmacists, nurses, allied, administrative, etc.), the care team members share reliable patient information for a better outcome. Advantage 2: the technology and the conception of the solution allow an industrial cloud-based delivery. The hospitals can have an affordable 365/7/24 services, and since the solution is highly configurable, it can be implemented to all-size hospitals from 50 to thousands of beds. Advantage 3: with hundreds of installations, our solution can meet a large panel of clinical specialties requirements: acute care, surgery, emergency, oncology, rehabilitation, mental health, elderly care, etc.). The modularity of the solution allows a progressive implementation. Advantage 4: we have developed with our clients and partners a field-proven implementation model based on a collaborative methodology. Our key success drivers are not only a powerful HIS platform, but also a large kn
SOFTWAY MEDICAL
Directeur GénéralErwan SALQUE
Nutrition and Weight Loss
Rare Disease
Your innovative solution
Remote surveillance system that improves the medical monitoring of patients treated by Peritoneal Dialysis and monitoring of the health of haemodialysis patients in self-dialysis structures.
Slow the progression to terminal Chronic Renal Insufficiency (CRI). Decrease the cardiovascular morbi-mortality.Helps management and evaluation .Better control over patient at lower cost Estimated annual savings of $10,000 per patient. Assistance with billing; more effective thanks to the control panels. Less hospitalisation.
E health / Care / Medical Devices
Selected as part of the Second e-Health call for projects under the French Government / expert systems / results
Pharmagest
E-Healt DirectorPhilippe VERWAERDE
Your innovative solution
We develop AZP2006 a first-in-class small molecule which modulates protein homeostasis. AZP2006 revolutionary mode of action has been shown to prevent Tau hyperphosphorylation and aggregation in vivo. Its nadditional neuroprotective properties allow to prevent both cognition and motor deficiencies induced by amyloid and other neurotoxics. AZP2006 will nter clinical phase 2 in 2016. It has obtained an orphan drug status for the treatment of PSP.
AZP2006 is developed for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease and Progressive Supranuclear Palsy.
Alzheimer's disease, Progressive supranuclear palsy, Frontotemporal dementia, Parkinson's disease
Innovative mode of action/ first-in-class candidate drug/ clinical phase / Orphan status
ALZPROTECT
CEOJerome WINDSOR
Your innovative solution
Our technology helps automate/standardize image interpretation ; it also enables quantification of standard imaging criteria and advanced imaging biomarkers, to provide early proof of treatment response. Our Lesion Management Solutions (LMS) platform is a proprietary suite of software modules for automated/semi-automated detection, quantitative measurement and follow-up of tumors.
MEDIAN's technology solves frequently observed issues in image interpretation such as intra- and inter-reader variability of measurement or lack of standardization of reading/interpretation processes. Both variability and insufficient level of standardization lead to a decrease of imaging data reliability, which can, for instance impact the statistical power of data in clinical trials.
Oncology drug development -clinical trials (phases I to phases III) / Novel biomarkers development in oncology and other therapeutic areas / Imaging based cancer screening programs
Quantitative and standardized data analysis supported by cutting edge, FDA approved, technology / Expertise in advanced imaging biomarkers for more accurate evaluation of drug efficacy / Real time, streamlined image workflow for clinical trials
MEDIAN Technologies
VP Business developmentTONY YAACOUB
Rare Disease
Rheumatology
Your innovative solution
Firalis has developed an integrated platform in its own laboratory located in Huningue, France. The platform includes a clinical testing laboratory, an assay development laboratory and a production site for critical reagents. The company is striving to develop bioanalytical tools such as antibodies, assay kits or microarrays that are meeting the highest standards of quality. The process leading to the design and production of these products is compliant with ISO 13485 standards, the international norm for medical devices
With a comprehensive expertise in the field, Firalis develops biomarkers and biomarker-based diagnostic kits to improve disease outcomes, patient comfort and therapeutic decisions; finally to generate remarkable savings in healthcare, which is the principal goal of biomarker services offered by Firalis. Our activities mainly but not exclusively involve biomarkers that are related to inflammatory disorders including common diseases such as atherosclerosis, rheumatoid arthritis or rare/orphan diseases such as systemic or autoimmune vasculitis
The services consist of biomarker R&D programs for clients such as pharmaceutical companies, biotechnology companies and public laboratories.
Novel values via biomarkers, discovery, cutting-edge platform, high quality standard
FIRALIS
CHIEF BUSINESS OFFICERFranck Zal
CNS-Neurology
Dental and Oral Health
Dermatology
Gastroenterology / Hepatology
Oncology
Ophthalmology
Orthopedics/Orthopedic Surgery
Pulmonary/Respiratory Diseases
Rare Disease
Your innovative solution
Hemarina develops products that constitute a decisive technological breakthrough in regard to current or past developments of hemoglobin-based oxygen carriers (HBOCs).
HEMOXYcarrier� = Universal oxygen carrier (Lack of blood worldwide is ~ 100 millions liters per year) - HEMO2Life : Organ & Tissue preservation - HEMHealing : Wound Healing & Repair
1/ Blood Oxygen Transporter, 2/ Organ & Tissue preservation, 3/ /Wound Healing & Repair
1/ Unique know how from development to production of oxygen carriers 2/ Strong academic network & partnerships 3/ Broad intellectual property covering Hemarina's technology 4/ international publications
Hemarina SA
CEOProf. Zyed ZALILA
CNS-Neurology
Dental and Oral Health
Dermatology
Endocrinology
Gastroenterology / Hepatology
Immunology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Nutrition and Weight Loss
Obstetrics/Gynecology (Women's Health)
Oncology
Ophthalmology
Orthopedics/Orthopedic Surgery
Otolaryngology (Ear, Nose, Throat)
Pediatrics/Neonatology
Pulmonary/Respiratory Diseases
Rare Disease
Psychiatry/Psychology
Rheumatology
Your innovative solution
Our xtractis' robot incorporates the latest advances in Artificial Intelligence, especially Fuzzy Logic and Machine Learning. It analyses a multidimensional database and automatically discovers robust fuzzy rule-based Decision Support Systems which are able to predict with the most reliability the complex process under study.
Robust Predictive Models for Epigenetics Personalized Medicine and Pharmacogenomics: Drug Discovery (efficiency, toxicity), Early Diagnosis, Companion Diagnostic, Virtual Screening, Selection of Best Target Patients, Disease Evolution, Survival Duration, Preventive Care, Environmental/Life-style/Diet/Therapeutic Recommendations, Side Effects & Adverse Events, Protein Homology, Reimbursement Rate of a Drug, Insurance Risk Scoring of a Patient
Pharmaceutical Industry / Personalized Medicine Diagnostics / Hospitals & Medical Centers / Private or Public Insurers
Unique mathematical approach (fuzzy, possibilistic, inductive, automatic, holistic, non-linear, non-monotonic, without a priori) / Proprietary algorithms implemented in fully automated software with user-friendly MMI / Better predictive capacity (robustness) vs. prevailing world-class techniques / Handles weak signals and low quality data